These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

655 related items for PubMed ID: 26923915

  • 1. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    Yiu ZZ, Warren RB.
    Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
    [Abstract] [Full Text] [Related]

  • 2. Oral small molecules for psoriasis.
    Singh S, Armstrong AW.
    Semin Cutan Med Surg; 2018 Sep; 37(3):163-166. PubMed ID: 30215633
    [Abstract] [Full Text] [Related]

  • 3. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R, Levin E, Koo J.
    J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
    [Abstract] [Full Text] [Related]

  • 4. Advances in treating psoriasis in the elderly with small molecule inhibitors.
    Cline A, Cardwell LA, Feldman SR.
    Expert Opin Pharmacother; 2017 Dec; 18(18):1965-1973. PubMed ID: 29171774
    [Abstract] [Full Text] [Related]

  • 5. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
    Caso F, Navarini L, Ruscitti P, Chimenti MS, Girolimetto N, Del Puente A, Giacomelli R, Scarpa R, Costa L.
    Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
    [Abstract] [Full Text] [Related]

  • 6. Tofacitinib in psoriatic arthritis.
    Wang TS, Tsai TF.
    Immunotherapy; 2017 Nov; 9(14):1153-1163. PubMed ID: 28967798
    [Abstract] [Full Text] [Related]

  • 7. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A, Mahmood F, Wittmann M, Helliwell P.
    Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
    [Abstract] [Full Text] [Related]

  • 8. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S, Kavanaugh A.
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [Abstract] [Full Text] [Related]

  • 9. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L.
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [Abstract] [Full Text] [Related]

  • 10. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
    Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M, study investigators.
    J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
    [Abstract] [Full Text] [Related]

  • 11. JAK inhibitors in chronic plaque psoriasis: What is known so far.
    Plachouri KM, Georgiou S.
    Drugs Today (Barc); 2020 Feb; 56(2):151-163. PubMed ID: 32163530
    [Abstract] [Full Text] [Related]

  • 12. The emerging safety profile of JAK inhibitors in rheumatic disease.
    Winthrop KL.
    Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Song GG, Lee YH.
    Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
    [Abstract] [Full Text] [Related]

  • 14. Small molecule therapy for managing moderate to severe psoriatic arthritis.
    Costa L, Del Puente A, Peluso R, Tasso M, Caso P, Chimenti MS, Sabbatino V, Girolimetto N, Benigno C, Bertolini N, Del Puente A, Perricone R, Scarpa R, Caso F.
    Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
    [Abstract] [Full Text] [Related]

  • 15. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.
    James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB, Lee LW, Merola J, Schwartzman S, Gladman D, Liu C, Koo J, Hawkes JE, Reddy S, Prussick R, Yamauchi P, Lewitt M, Soung J, Weinberg J, Lebwohl M, Glick B, Kircik L, Desai S, Feldman SR, Zaino ML.
    J Am Acad Dermatol; 2024 Aug; 91(2):251.e1-251.e11. PubMed ID: 38499181
    [Abstract] [Full Text] [Related]

  • 16. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1525-1536. PubMed ID: 29045207
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK, Cernea M, Lynde CW.
    Skin Therapy Lett; 2017 Mar 19; 22(2):1-7. PubMed ID: 28329404
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New systemic therapies for psoriasis.
    Mansouri Y, Goldenberg G.
    Cutis; 2015 Mar 19; 95(3):155-60. PubMed ID: 25844781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.